1H-MRS at 4 tesla in minimally treated early schizophrenia
about
Metabolic alterations associated with schizophrenia: a critical evaluation of proton magnetic resonance spectroscopy studiesNeurochemical changes in patients with chronic low back pain detected by proton magnetic resonance spectroscopy: A systematic reviewIn vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: application to schizophreniaIn vivo neurometabolic profiling to characterize the effects of social isolation and ketamine-induced NMDA antagonism: a rodent study at 7.0 T.Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysisT2 relaxation effects on apparent N-acetylaspartate concentration in proton magnetic resonance studies of schizophrenia.Imaging glutamate in schizophrenia: review of findings and implications for drug discovery.Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis.Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings.Hippocampal and thalamic neuronal metabolism in a putative rat model of schizophrenia.Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiationCortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investigated with Proton Magnetic Resonance Spectroscopy.Effects of Antipsychotic Administration on Brain Glutamate in Schizophrenia: A Systematic Review of Longitudinal 1H-MRS StudiesLong term antipsychotic treatment does not alter metabolite concentrations in rat striatum: an in vivo magnetic resonance spectroscopy study.Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies.Multivoxel proton MR spectroscopy used to distinguish anterior cingulate metabolic abnormalities in patients with schizophrenia.Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia.Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia.Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosis.Distinct neurometabolic profiles are evident in the anterior cingulate of young people with major psychiatric disordersGlutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla.Relationship between genetic variation in the glutaminase gene GLS1 and brain glutamine/glutamate ratio measured in vivoHigher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis.Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophreniaTranslating glutamate: from pathophysiology to treatment.Apoptotic markers in cultured fibroblasts correlate with brain metabolites and regional brain volume in antipsychotic-naive first-episode schizophrenia and healthy controls.Ketamine-Induced Modulation of the Thalamo-Cortical Network in Healthy Volunteers As a Model for Schizophrenia.Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophreniaAccuracy and stability of measuring GABA, glutamate, and glutamine by proton magnetic resonance spectroscopy: a phantom study at 4 TeslaRegional decoupling of N-acetyl-aspartate and glutamate in schizophreniaN-acetylaspartylglutamate (NAAG) and N-acetylaspartate (NAA) in patients with schizophreniaFrontal Glutamate and γ-Aminobutyric Acid Levels and Their Associations With Mismatch Negativity and Digit Sequencing Task Performance in Schizophrenia.Cross-sectional Study of Glutamate in the Anterior Cingulate and Hippocampus in Schizophrenia.Marine Ο-3 polyunsaturated fatty acids induce sex-specific changes in reinforcer-controlled behaviour and neurotransmitter metabolism in a spontaneously hypertensive rat model of ADHD.Age-related changes in anterior cingulate cortex glutamate in schizophrenia: A (1)H MRS Study at 7 TeslaTreatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive.N-acetylaspartate reduction in the medial prefrontal cortex following 8 weeks of risperidone treatment in first-episode drug-naïve schizophrenia patientsGlutamate and dopamine in schizophrenia: an update for the 21st centuryIn vivo measurements of glutamate, GABA, and NAAG in schizophreniaProton magnetic resonance spectroscopy of the substantia nigra in schizophrenia
P2860
Q26865740-2743C70A-8193-4159-ABDC-9D58051C368AQ28071253-399D29DE-8081-4EEB-B873-A5301E845A7AQ28083121-FA87C1CA-6C32-414D-BA75-688F96D4D1F3Q30413276-A26C206F-B0AC-4BF7-A65B-B62FE4BE5654Q30565982-544B6641-7444-463C-8C7C-FC64B33346F1Q30648464-0603B709-8B70-473B-8095-2DD9327A18C5Q30685335-CA0D7105-FA39-4246-B7A7-92FD280EABFCQ30712278-D76616E7-C5C7-416C-89D5-92369F709C87Q30732395-7AA7DF56-1737-4A53-8B57-F1F6083D16AAQ30849611-6EFFB9B1-57BE-410A-A698-F3F4B9E669D4Q30854782-A0A97FB3-D786-46F0-A5B6-F4E94A734021Q30993265-30180091-39E1-4BBB-8D15-4FA64A312FC5Q33611412-875F2F3A-5BAB-40ED-85AB-7325077B4106Q33853511-BF796805-231C-4B63-A5BF-A47BF83BDE04Q33957510-027F77FB-B523-40BB-A38B-70ABC9B79F98Q34013484-C53D18B3-5A17-4E0E-8C92-5997625D633BQ34048560-DC922F11-DFA5-4E31-B4B1-FA59C1919E46Q34193383-4CBE3E8C-AF7B-4CBB-9F07-23DD8F9BDAE1Q34270086-6BC9C096-2DA1-4166-AD38-AE930985C3FDQ34351880-54D23255-5FA8-4B71-A58F-72171816CE95Q34424470-A49C9C29-E688-4CD6-BE4E-9D502CA97F4DQ35074537-26FA3725-A6BE-444D-9A60-43A0D035ED85Q35158156-6D293703-8FAE-457D-8265-288C12B51061Q35626964-DA0EEE07-70EF-4EC7-AD85-9F11F6087103Q35739457-2C6BE6A4-2382-4FF9-A831-0B6E9A4A471BQ36043389-24DD8D0E-BFF7-4898-BB2B-660D76D597A8Q36077221-1122D54D-41AA-4989-ACB3-806E4ED74FBBQ36234271-3A8148F5-46ED-467F-A4FC-05B0DA835D3CQ36271096-43CC4700-11D1-418D-A628-A86127B4BFC5Q36323522-D7E6F280-1CFE-4909-8D31-B4F0DCB89E6DQ36471469-6DFA4725-113C-43BA-942C-88254B15872CQ36540578-025D8F2C-4265-4029-9694-11B81413D18DQ36579976-A4806B1E-4519-4677-ACF0-E266A9DF1D16Q36614190-40F91838-63D4-4E59-BA0A-6B462F0D11E7Q36767551-98697AE4-F182-4D4A-99E3-F3517B35A3D7Q36817154-BAD89FB9-4CD9-477D-A8E5-DE83B49179FEQ36972662-9EBAA0C7-1D4D-49C3-A99D-01E77C253F10Q36992322-D36A3966-EC5B-40A3-BC79-39747769B323Q37131013-F2DDFBC1-CFA7-4B3C-B6CD-5C9739A3648CQ37141400-598841DA-B712-47B6-B322-377BF5988EAA
P2860
1H-MRS at 4 tesla in minimally treated early schizophrenia
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
1H-MRS at 4 tesla in minimally treated early schizophrenia
@ast
1H-MRS at 4 tesla in minimally treated early schizophrenia
@en
type
label
1H-MRS at 4 tesla in minimally treated early schizophrenia
@ast
1H-MRS at 4 tesla in minimally treated early schizophrenia
@en
prefLabel
1H-MRS at 4 tesla in minimally treated early schizophrenia
@ast
1H-MRS at 4 tesla in minimally treated early schizophrenia
@en
P2093
P2860
P50
P356
P1433
P1476
1H-MRS at 4 tesla in minimally treated early schizophrenia
@en
P2093
P2860
P2888
P304
P356
10.1038/MP.2009.121
P407
P577
2009-11-17T00:00:00Z